Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals - PubMed (original) (raw)

. 2005 Sep;16(9):1065-74.

doi: 10.1089/hum.2005.16.1065.

Robert Walker, Charles S Carter, Ven Natarajan, Jorge A Tavel, Chris Bechtel, Betsy Herpin, Linda Muul, Zhili Zheng, Shyla Jagannatha, Bruce A Bunnell, Vicki Fellowes, Julia A Metcalf, Randy Stevens, Michael Baseler, Susan F Leitman, Elizabeth J Read, R Michael Blaese, H Clifford Lane

Affiliations

• PMID: 16149905
• DOI: 10.1089/hum.2005.16.1065

Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals

Richard A Morgan et al. Hum Gene Ther. 2005 Sep.

Abstract

The present study examined the safety and relative in vivo survival of genetically engineered CD4+ T lymphocytes in human immunodeficiency virus (HIV)-infected individuals. Ten pairs of identical twins discordant for HIV infection were recruited, with the uninfected twin serving as the lymphocyte donor. Ten subjects were treated with a total of 19 separate infusions of retroviral vector-transduced CD4+ enriched T cells. Control (neo gene) or anti-HIV gene (antisense trans-activation response [TAR] element and/or trans-dominant Rev)-engineered lymphocytes were monitored in peripheral blood for 3 years, using a vector-specific PCR assay. Data from 9 of the 10 patients (15 of the 19 infusions) demonstrated preferential survival of CD4+ lymphocytes containing the anti-HIV gene(s) in the immediate weeks after infusion. In six of six patients studied long term (>100 weeks), only T cells containing the anti-HIV genes were consistently detected. In addition, a marked survival advantage of anti-HIV gene-containing T cells was observed in a patient treated during a period of high viral load. Thus, these data strongly support the hypothesis that anti-HIV genes afford a survival advantage to T cells and potential benefit to HIV-1+ individuals.

PubMed Disclaimer

Similar articles

• Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients.
  Macpherson JL, Boyd MP, Arndt AJ, Todd AV, Fanning GC, Ely JA, Elliott F, Knop A, Raponi M, Murray J, Gerlach W, Sun LQ, Penny R, Symonds GP, Carr A, Cooper DA. Macpherson JL, et al. J Gene Med. 2005 May;7(5):552-64. doi: 10.1002/jgm.705. J Gene Med. 2005. PMID: 15655805 Clinical Trial.
• Adoptive transfer of syngeneic T cells in HIV-1 discordant twins indicates rapid regulation of T-cell homeostasis.
  Hoffmann C, Stellbrink HJ, Dielschneider T, Degen O, Stoehr A, Knechten H, Wolf E, van Lunzen J. Hoffmann C, et al. Br J Haematol. 2007 Feb;136(4):641-8. doi: 10.1111/j.1365-2141.2006.06478.x. Br J Haematol. 2007. PMID: 17223918
• A study of the safety and survival of the adoptive transfer of genetically marked syngeneic lymphocytes in HIV-infected identical twins.
  Walker R, Blaese RM, Carter CS, Chang L, Klein H, Lane HC, Leitman SF, Mullen CA, Larson M. Walker R, et al. Hum Gene Ther. 1993 Oct;4(5):659-80. doi: 10.1089/hum.1993.4.5-659. Hum Gene Ther. 1993. PMID: 8280803 Clinical Trial.
• The T cell receptor V beta repertoire in HIV-1 infection and disease.
  Soudeyns H, Rebai N, Pantaleo GP, Ciurli C, Boghossian T, Sékaly RP, Fauci AS. Soudeyns H, et al. Semin Immunol. 1993 Jun;5(3):175-85. doi: 10.1006/smim.1993.1021. Semin Immunol. 1993. PMID: 8102262 Review.
• T-cell therapies for HIV.
  Lam S, Bollard C. Lam S, et al. Immunotherapy. 2013 Apr;5(4):407-14. doi: 10.2217/imt.13.23. Immunotherapy. 2013. PMID: 23557423 Free PMC article. Review.

Cited by

• Advances in HIV Gene Therapy.
  Kitawi R, Ledger S, Kelleher AD, Ahlenstiel CL. Kitawi R, et al. Int J Mol Sci. 2024 Feb 28;25(5):2771. doi: 10.3390/ijms25052771. Int J Mol Sci. 2024. PMID: 38474018 Free PMC article. Review.
• Dominant Negative Mutants of Human Immunodeficiency Virus Type 1 Viral Infectivity Factor (Vif) Disrupt Core-Binding Factor Beta-Vif Interaction.
  Duan S, Yu X, Wang C, Meng L, Gai Y, Zhou Y, Gu T, Yu B, Wu J, Yu X. Duan S, et al. J Virol. 2022 Sep 14;96(17):e0055522. doi: 10.1128/jvi.00555-22. Epub 2022 Aug 11. J Virol. 2022. PMID: 35950859 Free PMC article.
• Automated production of CCR5-negative CD4+-T cells in a GMP-compatible, clinical scale for treatment of HIV-positive patients.
  Schwarze LI, Sonntag T, Wild S, Schmitz S, Uhde A, Fehse B. Schwarze LI, et al. Gene Ther. 2021 Sep;28(9):572-587. doi: 10.1038/s41434-021-00259-5. Epub 2021 Apr 19. Gene Ther. 2021. PMID: 33867524 Free PMC article.
• Tat-Based Therapies as an Adjuvant for an HIV-1 Functional Cure.
  Jin H, Li D, Lin MH, Li L, Harrich D. Jin H, et al. Viruses. 2020 Apr 8;12(4):415. doi: 10.3390/v12040415. Viruses. 2020. PMID: 32276443 Free PMC article. Review.
• Strong In Vivo Inhibition of HIV-1 Replication by Nullbasic, a Tat Mutant.
  Jin H, Sun Y, Li D, Lin MH, Lor M, Rustanti L, Harrich D. Jin H, et al. mBio. 2019 Aug 27;10(4):e01769-19. doi: 10.1128/mBio.01769-19. mBio. 2019. PMID: 31455650 Free PMC article.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Atypon

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program